IntelGenx Announces the Appointment of André Godin as President and Chief Financial Officer
May 08 2019 - 4:15PM
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT)
(“IntelGenx”), a leading oral drug delivery company, today
announced that its Board of Directors appointed André Godin to the
position of President in addition to his current position as the
Company’s Chief Financial Officer.
In his newly expanded role, Mr. Godin will have
overall responsibility for day-to-day operations, financial
reporting and budgeting, as well as managing the Company's
relationships and interactions with the investment community.
He will continue to report to the Company’s CEO, Dr. Horst G.
Zerbe.
“In the time that I have worked with André as a
member of IntelGenx’s senior management team, he has earned both my
deep personal admiration and great professional respect,” said Dr.
Zerbe. “André’s contributions to IntelGenx have already been
immeasurable and he is exceptionally well qualified to take on this
expanded role. I look forward to continue working with and support
him as we build on IntelGenx’s success.”
“I sincerely appreciate this additional vote of
confidence from the Board,” commented Mr. Godin. “Having built a
strong pipeline of innovative oral film products, I believe that
IntelGenx is approaching a stage of anticipated rapid growth. These
are exciting times and I am looking forward to us updating our
shareholders as we progress.”
Mr. Godin has an accomplished history of
financial and operational leadership success in the life sciences
industry. In an executive management career that spans close to
three decades, he most recently served as IntelGenx’s Executive
Vice-President and Chief Financial Officer. Before joining
IntelGenx in 2015, he was Interim CEO and CFO of Neptune
Technologies and Bioresources Inc. He started with Neptune in 2003
as Vice President, Administration and Finance and was named its CFO
in 2008. Prior to joining Neptune, he was President of a dietary
supplement company and Corporate Controller for an OTC
pharmaceutical products company. Mr. Godin is a member of the
Canadian Chartered Professional Accountants and the Canadian
Institute of Chartered Accountants. He holds a Bachelor of Business
Administration degree from Université du Québec à Montreal.
About IntelGenx
Established in 2003, IntelGenx is a leading oral
drug delivery company primarily focused on the development and
manufacturing of innovative pharmaceutical oral films based on its
proprietary VersaFilm® and VetaFilm™ technology platforms.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility, which was established for
oral film technology platforms, offers by supporting lab-scale to
pilot- and commercial-scale production. More information about the
company can be found at www.intelgenx.com.
Forward Looking Statements
This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTCQX has
neither approved nor disapproved the contents of this press
release. Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Source: IntelGenx Technologies Corp.
For IntelGenx
Stephen Kilmer
Investor Relations
(514) 331-7440 ext 232
stephen@intelgenx.com
Or
Horst Zerbe
CEO
IntelGenx Corp.
(514) 331-7440
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Sep 2023 to Sep 2024